{"groups":[{"description":"Allogeneic stem cell transplant for patients with hematologic malignancies: The randomization was stratified equally for the first 100 patients at study entry and conditioned regimen with Fludarabine/Timed Sequential (TS) Busulfan AUC 16,000umol/l vs. Fludarabine/Timed sequential Busulfan AUC 20,000umol/l.","id":"FG000","title":"Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l"},{"description":"Allogeneic stem cell transplant for patients with hematologic malignancies: The randomization was stratified equally for the first 100 patients at study entry and conditioned regimen with Fludarabine/Timed Sequential (TS) Busulfan AUC 16,000umol/l vs. Fludarabine/Timed sequential Busulfan AUC 20,000umol/l.","id":"FG001","title":"Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l."}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"151"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"49"},{"groupId":"FG001","numSubjects":"150"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were recruited from April 2012 to December 2015 at MD Anderson Cancer Center."}